Re-programming the tumour
environment to change outcome
The company was founded on a simple but far-reaching observation from Professor Melinda Duer's laboratory: the molecular state of the matrix surrounding a tumour can shape how that tumour behaves, and, in principle, that state can be modified or ‘re-programmed’.
Science-led,
commercially validated
We believe that in whatever we do, it has to be deeply rooted in science first and foremost, and then validated commercially to maximise translational success.
Creating a new oncology
therapeutic layer
Our ambition is to build a first-in-class oncology platform predicated on creating a new but complementary therapeutic layer in treating solid tumour cancers.
If the matrix is mechanism rather than scenery, then it is also a target. And if it can be modified, it can be treated.
Biology first.
Platform second.
Scale third.
The order of those three words matters. Biology first means the science leads and the platform follows from it, rather than a technology going in search of a disease.
Platform second means what is built has to be reusable. A single asset in a single indication is a product; a way of reading and modulating the matrix across ECM-rich solid tumours is a platform, and the second is what justifies the effort of starting from first principles.
Scale third is a statement about sequence rather than ambition.
Preclinical,
and progressing.
Ecmera was founded in July 2026, and its programmes are in preclinical development, translating laboratory findings into a therapeutic candidate.
Ecmera brings together two decades of academic work, a specific and testable hypothesis about the tumour microenvironment, a lead indication chosen as the toughest test of the idea, and three founders with the background to pursue it.
Read it.
Modulate it.
Complement it.
Aim at features the tumour matrix shares, rather than one receptor on one kind of cell.
Reprogramme how cancer cells behave by changing what the matrix tells them.
A new layer that works alongside existing treatment.